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A PATIENT-CENTRIC DATA ANALYSIS: APPLICATION OF A N-OF-1 
ANALYSIS IN A PEDIATRIC PAIN INTERVENTION 
MICAH JOSEPH LUDWIG 
ABSTRACT 
 Making evidence-based treatment recommendations is very important for 
clinicians across all medical specialties. This becomes increasingly difficult when taking 
into consideration the specific characteristics of each individual patient. Most evidence-
based knowledge comes from randomized control trials, which often overlooks unique 
individual concerns. A single case methodology, which assesses treatment responses in 
individual patients, allows clinicians to collect statistically rigorous data, but also assess 
improvement in individual patients. In our investigation we show that a single case 
methodology, using four different analyses, can be applied to assess the efficacy of a 
CBT intervention delivered to pediatric chronic pain patients. We demonstrate that such a 
methodology, when we combine results from multiple statistical tests, allows us to make 
conclusions about treatment responses. Furthermore, we show that our intervention 
targets several different issues chronic pain patients face, in particular the avoidance of 
painful activities. While we did see congruence of results across the different statistical 
analyses, there were also several examples of inconsistency. These inconsistencies seem 
to occur when patients show considerable variability in their responses to the questions 
on the daily measures, introducing ‘noise’ that made detecting ‘true signal’ (treatment 
response) quite difficult.  
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INTRODUCTION 
 The use of evidence-based decision-making is becoming increasingly 
important across medical settings (Tsapas & Matthews 2009). In conjunction there is a 
shift toward personalized medicine, tailoring treatments to best meet the needs of an 
individual patient (Norcross et Wampold 2009). Thus we are left to surmount the 
challenge of using an evidence-based approach while ensuring our interventions are 
uniquely tailored to the patient before us. Typically we rely on results from randomized 
controlled trials to ascertain if a given treatment is effective. However, individuals within 
a controlled trial could differ markedly from a given individual for who you are making 
therapy recommendations. For example, there could be more comorbidity amongst the 
patients you are treating in clinic or simply different combinations of comorbidities (Kent 
et al 2010). Thus generalizing results from controlled research to clinical practice 
presents a real challenge. Furthermore, we may have an inherent understanding that 
individualizing treatment is important, but we might struggle in rigorously evaluating 
what specific therapy is best for a certain patient. The clinician then may rely on his/her 
intuition and prior experience. This again presents an issue, as it could be difficult to 
generalize outcomes from previous patients to the one you are currently treating. 
Treatment decisions in the clinic can also be plagued by the fact that patients are 
evaluated largely on impressions of the clinician, instead of systematic observations 
coming from validated measures. When systematic measures are not used the reliability, 
validity, and replicability of results can be disputed (Duan et al 2013).  Therefore, both 
research and practice, have issues about what can be inferred, generalized, and applied to 
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patients. Controlled experimental research gives the needed rigor to adequately measure 
effects of a given intervention. Included in this rigor are factors such as control of the 
intervention, statistical significance, and precision in evaluating outcomes (Duan et al 
2013).  From experience we know that every patient is unique and that tailored 
interventions are desirable, but the factors mentioned above may in some ways be at odds 
with a tailoring treatment.  
 
Randomized Clinical Trials: Pitfalls of the gold standard 
Presently, the gold standard for evaluating the usefulness of a treatment is the 
between-subject randomized controlled trial or RCT (Schwartz et al 2004). RCTs are 
typically used to determine whether a treatment or intervention is beneficial in 
comparison to a control. Eligible patients are randomly assigned to either the control or 
treatment arm of the study. The goal of this is to minimize allocation bias, thus ensuring 
any differences in effects are due to the intervention and not inherent differences between 
the two groups. Clearly when we are thinking about evidence based decision-making it is 
important to eliminate potential biases that may compound the real effects of a given 
treatment. IHowever, trials of this nature are not immune to flaws. RCTs do not always 
translate well to clinical practice as patients with unique comorbidities are often not 
included within these trials (Lillie et al 2011). This is done to increase internal validity of 
the study but comes at the cost of decreasing generalizability. Another fundamental issue 
with RCTs is that they only give an estimate of the between-subject treatment response 
(the average difference between the two groups). Thus it is difficult to determine how a 
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specific individual responded to a given treatment. An individual participant in a RCT 
could have shown no improvement, had an adverse reaction to the treatment, or benefited 
from the control (which was shown to be statistically inferior) (Lillie et al 2011). The 
issue is that it becomes difficult to predict whether an individual patient is more similar to 
a responder or non-responder for the intervention in question. This concept is known as 
heterogeneity in treatment effects (HTE), and presents a real issue to clinicians who care 
most about an individual patient (Kent et al 2010). Knowing what is going to be most 
beneficial for their patient is the primary objective of a clinician, instead of what 
intervention on average is most beneficial for a group of patients. Simply taking an 
average of treatment response between the two groups masks individual differences 
between patients. One solution is to group patients into subgroups, with the hope to gain 
a better appreciation for differences in treatment response between individuals (Davidson 
et al 2014). The thought is that by making smaller and smaller subgroups eventually 
individuals within a given group will be interchangeable (Davidson et al 2014). One issue 
with this is how to make the subgroups, especially when there is overlap in comorbidities 
(all of which may affect treatment response). Additionally, when it comes time for a 
clinician to make a treatment decision it can be difficult to determine which subgroup 
best matches their patient.  
 
The clinician’s dilemma 
Davidson et al 2014 present an interesting scenario in which a clinical psychology 
intern is presented with a patient with a constellation of symptoms including ADHD, for 
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which he is prescribed Ritalin. Despite increases in the patient’s medication the patient is 
still not experiencing any symptomatic improvement. The clinician consults the literature 
to determine what decision they should take on this particular patient, but discover that 
all the results from multiple RCTs are not germane enough to this particular patient’s 
situation (patients with significant comorbidities were excluded). They then look for 
studies that used a subgrouping methodology to match their patient, but to no avail. Now 
the clinician, unable to use an evidence-based approach for this patient, is forced to rely 
on a best-guess approach based on past experience and an understanding of the patient as 
an individual. A trial and error approach could be taken until an effective treatment is 
found for this particular patient. This approach, although with some scientific merit, is 
prone to multiple biases. If there is not an appropriate control you cannot determine if 
perceived improvement was due to the treatment or just part of a long-term trend. 
Although the clinician wishes to practice evidence based medicine, realizing RCTs are 
good at eliminating potential biases and showing causality, they have concern those 
studies may not reliably predict the outcome for this particular patient. Wanting to take a 
tailored approach to treating their patient they decide to come up with a personalized 
plan. However, by lacking a rigorous experimental design in the delivery of treatment 
they have no reliable way to predict what actually worked for this patient. What is needed 
is a methodology that is patient-centric, but still possesses experimental rigor and 
minimizes biases.  
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The ‘case’ for single case analysis 
Single-patient trials (or N-of-1 trials) are one methodology to address some of the 
concerns associated with RCTs and ensure a rigorous approach to tailored treatments 
(Larson 2010). Developing medical interventions that work ubiquitously is difficult, and 
a personalized approach is necessary. Having an experimental design and data analysis to 
match this approach is paramount. In an N-of-1 trial a single patient is the unit of 
observation for assessing the efficacy of an intervention (Duan et al 2013). Through a 
review of the literature from 1985-2010, Gabler et al 2010 report 108 studies using an N-
of-1 design. Conditions in which an N-of-1 design has been successfully implemented 
include fibromyalgia, chronic pain, asthma, insomnia, chemotherapy-associated nausea 
and vomiting, and ADHD, providing support for its applicability in a variety of settings. 
N-of-1 defined. Typically in an N-of-1 study there is a baseline period for each 
patient, which is then compared to a treatment period. The methodology can also be used 
to compare different treatments for a given patient, each of which would have an 
associated baseline period. The patient and clinician could then make a decision about the 
best treatment to meet a patient’s specific needs based on the N-of-1 data. Different from 
RCTs N-of-1 trials can be used to estimate individual treatment effects directly (Lillie et 
al 2011). Built into an N-of-1 trial is a mechanism of repeated data collection during both 
the baseline and treatment periods, allowing the experimenter to track the progress of an 
individual subject. This translates into a more intensive data collection method in 
comparison to population-based studies (Shaffer et al 2015). The data collected can be 
analyzed using visual inspection techniques, but sophisticated time-series analyses are 
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often employed (Shaffer et al 2015). Such analyses take into account that adjacent time 
points will have a strong correlation with each other. Accordingly, the time series 
analyses provide statistical rigor and accommodate the unique nature of taking repeated 
measurements across a short interval of time.  
Advantages of the N-of-1 approach. An advantage to the N-of-1 methodology is 
that it gives patient specific clinical knowledge that can be used to make decisions about 
future treatment and interventions. As evidenced by subgrouping patients within an RCT, 
there is a great variability in the efficacy of interventions across groups. Extending this 
knowledge further we can reason there is significant variability across individuals as 
well. What an N-of-1 trial does is account for this variability objectively, and at the same 
time produces an informed decision regarding treatment for an individual patient 
(Davidson et al 2014). 
Another advantage of the N-of-1 analysis becomes apparent when we consider 
conditions in which getting an adequate population size may be difficult due to 
recruitment barriers. The RCT requires a large sample size in order to make claims about 
statistical significance, whereas an N-of-1 analysis allows for statistical claims to be 
made regarding an individual patient (Nikles et al 2011). This is due to objectively 
tracking a patient’s condition continuously through a baseline and treatment phase (the 
patient serves as their own control). When we were considering the clinician forced to 
rely on their clinical impressions and intuition for decision-making they lacked a rigorous 
way to see if their patient was improving due to the intervention. However, if the 
clinician had applied a N-of-1 methodology they would have statistical evidence about 
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the efficacy of the intervention. N-of-1 studies may also be particularly relevant in 
helping individuals suffering from more chronic conditions. Such conditions generally 
require a tailored approach to treatment and a fair amount of trial and error to determine 
the best treatment (Duan et al 2013). Using an N-of-1 approach could help facilitate 
coming to this decision more efficiently and eliminate much of the “guess work.”  
Group-level conclusions through N-of-1 meta-analysis. One objection to an N-of-
1 trial may be that while it does provide meaningful data about an individual subject, how 
can the information gathered be applied to future patients? Fortunately, there are methods 
one can use to conduct a meta-analysis on multiple N-of-1 trials that are assessing the 
same intervention. Through these analyses you could discover trends in the data, which 
might demonstrate the types of patients that responded to a given intervention. Zucker et 
al 2010 discuss a Bayesian mixed-model approach to combine N-of-1 trials to make 
population level conclusions regarding different interventions. In some ways combining 
multiple N-of-1 trials to determine patterns among responders may sound similar to 
RCTs and subgrouping patients. However, the difference is that the N-of-1 approach is 
more focused, allowing to gain insights, which can benefit a larger group of patients 
(Nikles et al 2011). Potentially this could be more efficient than the RCT methodology in 
which a large net is casted hoping to find defining characteristics about patient 
responders.  If enough N-of-1 trials are done to elucidate characteristics of treatment 
responders and then combined using a meta-analysis it may be possible to identify 
patients that could benefit from a given treatment (Shaffer et al 2015).    
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Other advantages of the N-of-1 approach include the allowance of some 
heterogeneity in design, which is not a possibility in large population-based trials (Shaffer 
et al 2015). These trials require uniformity to prevent any confounders. With this design 
patients can also benefit immediately from the results of the trial, helping them to make 
educated decisions about future treatment. An N-of-1 trial could also be used to 
determine whether a larger more costly population-based trial is warranted (Shaffer et al 
2015). 
 As suggested by the Evidence-Based Medicine Working group N-of-1 trials 
provide strong evidence for patient decisions. They argue that N-of-1 trials can provide 
scientifically valid results that patients and providers can use to make optimal treatment 
decisions and overcome the heterogeneity of treatment effects that plague RCTs. Nikles 
et al 2005 report that in a N-of-1 study of 71 patients with chronic pain or osteoarthritis, 
46 patients (in discussion with their physician) decided to change their medication and 12 
decided to stop taking the medication based solely on their N-of-1 results; thus 
demonstrating the applicability of the N-of-1 approach on medical decision-making. 
Although there is a proliferation in the use N-of-1 trials in the medical literature, they 
continue to only be used sporadically for clinical decision-making (Shaffer et al 2015). In 
an effort to provide both evidence based and patient tailored treatments greater work 
needs to be done to demonstrate the use of N-of-trials in a variety of interventions. 
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Applying N-of-1 methodology to cognitive behavioral interventions 
When considering how we assess the efficacy of psychotherapy interventions the 
shortcomings of RCT and the need for an N-of-1 model become apparent. The RCT 
model does not reflect how providers work on a daily basis, thus hindering clinical 
implementation (Schwartz et al 2004).  In order for an intervention to become a part of 
the standard of care we must demonstrate the efficacy, and assessing efficacy requires a 
proper methodology. An N-of-1 model could be very beneficial in assessing the efficacy 
of certain psychological interventions, including cognitive behavioral therapy. These 
interventions are inherently tailored making the “gold standard” of uniformity in an RCT 
less feasible.  In cognitive behavioral therapy a provider helps patients confront and 
modify certain thoughts and beliefs which could be resulting in maladaptive behavior. 
Such maladaptive behaviors often result in patients living a less fulfilling life. The 
therapy can include methods such as goal setting, development of adaptive coping 
strategies, and changing maladaptive beliefs about a certain condition. Given this 
heterogeneity in CBT determining efficacy and identifying the most salient aspect of 
therapy can be difficult. Maric et al 2015 used a single case analysis to assess the 
efficacy of CBT in children and adolescents suffering from anxiety. Interestingly in their 
approach they used a single case design to investigate changes for a single patient in 
response to different aspects on the intervention. For example, observing the patient’s 
response to just exposure therapy and then to exposure in conjunction with cognitive 
therapy. They found that CT and EXP (exposure) were more effective than just EXP. 
Although they did not do this in their study they do suggest the possibility of using a 
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single case analysis to investigate the effects the order of an intervention could have on 
patient response. A single case design could allow an investigator to track a patient’s 
response to different components of a CBT intervention, giving insight into what part of 
therapy was most salient. Maric et al 2012 explain that in the treatment of anxiety there is 
50 years of evidence that CBT is efficacious as a whole treatment package, but there is 
little insight into, which particular aspect of CBT is driving the change. For practical 
reasons such questions could be difficult to explore using a traditional RCT methodology. 
There is likely to be variation between individual patient’s responses to different aspects 
of CBT. With the case presented by Maric et al 2015 one patient might benefit more 
from CT, while another may benefit from exposures only. These nuanced differences 
would be lost in RCT designs (Gaynor & Harris 2008). Pollock et al 2013 employed a 
single case design to assess the efficacy of CBT in a cohort of hoarding disorder patients. 
This study was a two year time series using an ABC design, where A=baseline, and B 
and C two different variations of the intervention. A single case design allows a clinician 
to track a patient’s response over a significant period of time, and to compare different 
treatments for an individual. From this we see that a single case design can be very 
beneficial to determining efficacy in the context of CBT intervention, as treatment may 
extend over a significant amount of time and the clinician may frequently make changes 
to best suit the patient.     
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Applying N-of-1 methods to CBT for Chronic pain 
Cognitive behavioral therapy has often been used to treat chronic pain. Chronic 
pain is influenced by biological, psychological, and social factors and often occurs with 
other symptoms such as sleep disturbance, anxiety, and depression, which can actually 
exacerbate the pain (Knoerl et al 2015). All of this can lead to a decrease in quality of life 
and physical function. CBT is uniquely posed to address some of the concerns associated 
with quality of life and learning to live a fulfilling life in the context of pain. However, 
more work is needed to determine the best way to deliver CBT to chronic pain patients. 
For example, determining which CBT doses, delivery methods, strategies, and follow-up 
doses are most efficacious is vital (Knoerl et al 2015). Central to determining this though 
is how to actually assess efficacy. In this paper we will demonstrate how to use a N-of-1 
analysis model to assess the efficacy of a cognitive behavioral intervention in pediatric 
chronic pain patients. The particular CBT we are using is very unique in that a clinical 
psychologist will be working in conjunction with a physical therapist to deliver the 
intervention. Additionally, the intervention is tailored to individual patient’s specific 
needs making an N-of-1 analysis very applicable. A chief goal of this paper will be to 
provide evidence that an N-of-1 analysis could be used to assess the efficacy of similar 
interventions. A secondary aim of the paper will be actually assessing how effective the 
CBT was at improving patients on a variety of measures. It is hypothesized that the N-of-
1 approach will be an appropriate analysis to uniquely capture the nuances in patient 
improvement on daily measures and that patients the vast majority (> 75%) of patients 
will demonstrate clinically significant improvements after treatment. Demonstration of 
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this analysis approach may help inform future treatment decisions and better tailor the 
pain intervention to patient’s needs. 
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METHODS  
 
Participants 
Participants (aged 8-21) with musculoskeletal, neuropathic, or headache pain and high 
pain-related fear (score >40 on Fear of Pain Questionaire (Simons, Sieberg, Carpino, et al 
2011) were recruited from a Pain Treatment Service after presenting for a 
multidisciplinary evaluation of their chronic pain. Patients recruited also had a score of 
greater than 12 on the Function Disability Inventory (FDI(Kashikar-Zuck, Goldschneider, 
Powers, Vaught, & Hershey, 2001; L.S; Walker & Greene, 1991). Individuals with pain 
due to acute trauma or any specific systemic disease were excluded from the study. 
Additional exclusion criteria included presence of significant cognitive impairment or 
serious psychopathology.  In order for participants to engage in the exposure component 
of the study they had to be cleared by a physical therapist.   
 
Procedure 
Following being consented for the study, participants were randomly assigned to a 
baseline period ranging from 7-21 days. During this time they completed daily measures. 
Following baseline GET Treatment began, which consisted of 45-minute sessions 
facilitated by a cognitive-behavioral pain psychologist and physical therapist. The first 
four sessions consisted of patient education on the fear avoidance model of pain and goal 
setting for the participant. At session five exposures began, during which participants 
were gradually engaging in activities they typically avoided due to their pain. Treatment 
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could be terminated early if the clinician and participant felt treatment goals had been 
reached. Participants also completed daily measures at a 3 month and 6 month follow-up.   
 
Measures 
Daily Diary Data Collection 
 
Patients completed daily diaries during a randomized baseline period ranging 
from 7-21 days, during treatment, and also for a seven-day period at 3-month and 6-
month follow-up. By doing this patients served as their own control enabling the use of 
an N-of-1 data analysis approach. The daily diaries were self-report surveys consisting 12 
of items that were rated on a 5-point Likert-type scale from 0 to 4. Daily Diary items 
were derived from full-length validated questionnaires that assess the following 
constructs: fear of pain (3 items), avoidance of activities (2 items), pain catastrophizing 
(3 items), pain acceptance (3 items), and pain level (1 item). Pain catastrophizing is 
defined as the tendency for an individual to describe their pain in exaggerated or 
hyperbolic terms. Daily diaries were sent to patients via email and completion was 
monitored continuously during all phases. Results of the surveys were compiled each day 
to yield a total score for fear, avoidance, catastrophizing, acceptance, and a pain level. 
 
Statistical Analyses 
For each domain of the daily diary the following analyses were completed: visual 
analysis, single case randomization test, lag analysis, and effect size.  
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Visual Analysis. For each patient a line graph was constructed to show the daily 
diary results during baseline, treatment, and follow-up. For visual simplicity, averages are 
presented rather than daily results. Baseline and follow-up time points are subdivided in 
7-day increments and during treatment, the average reflect days between each treatment 
session. The graphs were analyzed through visual inspection to determine any noticeable 
trends in participants’ reporting of their fear, avoidance, acceptance, catastrophizing, and 
pain score. 
Single Case Randomization Test. Using the SCRT package in R a single 
randomization test was completed for each domain of the daily diaries for each patient. 
This test evaluated the null hypothesis that no significant changes existed between 
measurement times when comparing baseline and treatment values. Additionally, this test 
was completed to compare baseline and follow-up periods. The analysis is a time series 
method for determining significant differences, therefore accommodating for correlations 
between adjacent time points. A significant change was defined as a p-value less than 
0.067, which reflects the probability associated with being assigned a given baseline 
length ranging from 7 to 21 days.    
Lag analysis. The single randomization test was repeated, again using the SCRT 
package in R, to determine at which point in treatment a significant change was seen. 
This is accomplished by sequentially grouping individual treatment values with baseline 
values when conducting the randomization test. Additional treatment values were 
grouped with baseline values until a significant change was observed (p< 0.067).  
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Effect size. Effect size, which measures the extent data from two time periods 
overlap, was calculated using the SCDA package in R. Non-overlapping of all pairs 
(NAP) was used as a way to calculate effect size. NAP equals the number of comparison 
pairs divided by the total number of comparisons. For each domain NAP was calculated 
comparing baseline to treatment, baseline to follow-up, and treatment to follow-up. To 
calculate NAP we compare each phase A data point with each phase B data point, thus 
the total number of possible pairs would be number of data points in phase A times the 
number of data points in phase B. If there is overlap between two pairs a value of 1 is 
assigned (for a measure in which we expect a decrease in score overlap would be defined 
as a data point in phase B being higher than phase A data point), if the two data points are 
equal a value of 0.5 is assigned. So if we had 10 phase A and 20 phase B data points the 
total number of pairs would be 10 x 20= 200 pairs. Of these pairs if there were 4 pairs 
that overlapped and 3 that were equal to each other the NAP would equal: [200-((4*1) 
+(3*0.5))]/200= 0.97. This means 97% of the data points between the two phases are 
non-overlapping.   
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RESULTS 
 
 
Participants 
Twelve participants were recruited from the pain treatment service. Pain 
diagnoses included neuropathic pain, CRPS, headache, musculoskeletal pain, and 
abdominal pain. Duration of pain for participants ranged from 9 to 96 months. 
Participants were primarily female (75%) and the average age was 13 years. Number of 
treatment sessions ranged from 9-14, with the total length of the treatment period ranging 
from 47-107 days. Notably, T1 was assigned two baseline periods, as the patient was not 
yet cleared by physical therapy to begin exposures after completing the initial four 
education sessions. The second baseline period consisted of the length of time between 
session 4 and the introduction of exposures in session 5. Patient demographics and 
treatment information are summarized in Table 1.  
 
Table 1.  Patient Demographics. Summary of participant demographics, diagnosis, and treatment 
information. 
Patient Gender Age 
Duration 
of Pain Diagnosis 
# of 
Treatment 
Sessions 
# of 
Treatment 
Days 
T1 Female 13 12 m CRPS right wrist 
         9 (+4 
psych only 
sessions) 197 
T2 Male 16 24 m 
thumb pain; 
neuropathic 9 40 
T3 Female 21 12 m 
kidney pain; left 
flank pain; IBS 12 71 
T5 Female 17 12 m abdominal pain; IBS 12 64 
T6 Female 10 9 m CRPS Knee 9 113 
T7 Female 13 60  head; joint pain 12 47 
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T9 Female 16 12 m CRPS right foot  12 84 
T10 Female 16 60 m  CRPS ankle/foot  12 78 
T12 Female 8 6 m entire back 12 128 
T13 Male 10 84 m headache 13 71 
T15 Female 11 96 m 
back; widespread 
musculoskeletal 14 71 
T17 Male 8 4 m abdominal pain 11 46 
Note. M=months 
 
 
Visual analysis 
Figure 1 shows time series graphs demonstrating the trends across the five 
domains of the daily diaries for each patient.  
Fear. Of the 12 patients, four reported decreased fear scores during treatment with 
these changes maintained at one (T5) or more follow-ups (T1, T2, T9). For five 
additional patients decreases in fear emerged at one (T6, T7, T12) or more follow-ups 
(T13, T17). Three patients reported no improvements in fear across time (T3, T10, T15). 
While 10 of the 12 patients had no changes in fear during the baseline period, two 
reported decreased fear during the baseline and were in the fear nonresponder group 
(T10, T15). Altogether from visual inspection, 75% of patients reported decreased fear at 
the end of treatment and/or follow-up.  
Avoidance. Six patients reported decreased avoidance scores during treatment 
with changes maintained at one (T12) or more follow-ups (T1, T2, T6, T9, and T13). 
Four additional patients showed a decrease at one (T5) or more follow-ups (T3, T7, and 
T17). Notably, T7 did show a small decrease in avoidance during baseline. No decrease 
in avoidance was seen for two participants (T10 and T15) across treatment and at both 
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follow-up periods. From visual inspection 83% of patients had decreased avoidance 
scores during treatment and/or follow-up.   
Acceptance. Of the 12 patients three patients reported increases in acceptance 
scores during treatment, with increases being maintained during both follow-up periods 
(T1, T6 and T2). Two patients (T5 and T13) showed improvement in acceptance during 
treatment and then further increases at one (T5) or more (T13) follow-ups. Of note T2 
and T5 showed some increase in acceptance during baseline, but further increases were 
reported during treatment. Four patients showed improvement in acceptance at one (T17 
and T10) or more (T7 and T15) follow-ups. Two patients (T3 and T9) showed no 
increase in acceptance and one patient had a decrease in acceptance (T12). Altogether 
visual analysis indicates 75 % of patients had an increase in acceptance during treatment 
and/or at follow-up.   
 
Catastrophizing. Four patients reported decrease catastrophizing scores during 
treatment (T1, T6, T9 and T15), with decreases being maintained at follow-up. An 
additional three patients reported decreased catastrophizing at one (T7) or more (T10 and 
T17) follow-up time period. No decrease in catastrophizing was demonstrated for four 
patients (T2, T3, T5, and T13), with patients T2 and T3 exhibiting an increase in 
catastrophizing during baseline. Interestingly, patients T12 and T13 exhibited an increase 
in catastrophizing when comparing treatment to baseline, and a decrease when comparing 
treatment to follow-up. Based on visual analysis 58% of patients reported a decrease in 
catastrophizing during treatment and/or at follow-up.  
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Pain Score. Based on visual analysis seven patients showed a decrease in pain 
during treatment (T1, T2, T6, T9, T12, T13, and T17), with four patients maintaining 
decreases at both follow-up periods (T1, T2, T9 and T17) and two patients with decreases 
maintained at three-month follow-up (T12 and T13). One patient (T6) showed further 
decreases in pain at both follow-up periods. Two patients reported decreased pain scores 
at three-month and six-month follow-up (T10 and T15), with patient T5 reporting 
decrease at three-month follow-up. Notably T15 had an increase in pain during treatment.  
No decrease in pain was seen for two patients (T3 and T7). Visual analysis indicates that 
83% of patients exhibited a decrease in their pain scores during treatment and/or at 
follow-up. 
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Figure 1: Daily Diary Time Series Graphs. Time series graphs for each patient showing their 
reporting across the five domains of the daily diaries: fear, avoidance, acceptance, catastrophizing, 
and pain. Averages were reported instead of the result for each individual day for presentation 
purposes. Each baseline time point represents an average seven day increments. Treatment time 
points are an average of daily results between each treatment session. Three month and 6 month 
follow-up points are the average of the results during each 7-day window during the follow-up 
period.  
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Single Case Randomization Test 
Treatment to baseline. Results from the single case randomization test to 
determine differences between baseline and treatment revealed significant decrease (p < 
0.065) in fear scores among two patients (T6 and T15) and avoidance for one patient 
(T6).  It is important to note patient T15 began to show decreases during baseline. The 
only significant difference for acceptance was an increase (T1). Four patients had 
significant decreases in catastrophizing (T2, T3, T6, and T15) and three patients (T2, T6, 
and T15) had significant decreases in pain. Results are summarized in Table 2.  
 
Table 2.  Baseline to Treatment Randomization Test.  Results from randomization test determining 
significant differences between baseline and treatment for the five domains of daily diaries for each 
patient. *indicates change was in direction opposite from expected 
Patient Fear Avoidance Acceptance Catastrophizing Pain Score 
T1 
        
0.92,0.46         0.92, 0.43      *0.052,0.56             0.92, 0.46          0.90, 0.74 
T2 0.48 0.28 0.85 0.05 0.03 
T3 0.09 0.98 0.93 0.02 0.1 
T5 0.52 0.48 0.33 0.45 0.21 
T6 0.04 0.06 0.74 0.04 0.03 
T7 0.88 0.15 0.83 0.1 0.59 
T9 0.98 0.99 0.98 0.99 0.15 
T10 1 0.2 0.34 0.79 0.3 
T12 1 1 0.26 1 0.96 
T13 0.75 0.96 0.11 0.83 0.44 
T15 0.03 1 1 0.03 0.05 
T17 0.82 0.78 0.24 0.27 0.73 
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Baseline to follow-up. Presented in Table 3 are the results from the randomization 
test determining significant differences (p<0.065) between baseline and both follow-up 
periods. T1 had significant decreases in fear, avoidance, catastrophizing and pain at 6-
month follow-up. Two other patients (T2, T5), reported significantly lower avoidance at 
3-month follow-up. Lastly, T10 reported significantly lower catastrophizing and pain at 
both follow-ups compared to baseline. 
 
Table 3. Baseline to Follow-up Randomization Test. Randomization test results to determine 
significant differences between baseline and both follow-up periods (A=baseline, C1= 3 month, C2= 6 
month. 
Patient Fear Avoidance Acceptance Catastrophizing Pain Score 
T1           
  A-C1 0.09, 0.05 0.08, 0.05 1.0, 1.0 0.09, 0.05 0.09, 0.05 
  A-C2 0.06, 0.05 0.06, 0.05 1.0,1.0 0.06, 0.05 0.06, 0.05 
T2           
  A-C1 0.55 0.06 0.88 0.18 0.09 
  A-C2 1 0.18 0.82 0.45 0.06 
T3           
  A-C1 1 0.2 0.2 0.2 1 
  A-C2 1 0.2 0.2 0.2 1 
T5           
  A-C1 0.2 0.03 1 1 0.2 
  A-C2 0.2 0.2 0.2 1 1 
T6           
  A-C1 1 0.25 1 0.25 0.25 
  A-C2 1 0.2 1 0.25 0.25 
T7           
  A-C1 0.17 0.17 1 1 1 
  A-C2 0.17 0.17 1 0.2 0.6 
T9           
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  A-C1 1 1 1 1 1 
  A-C2 0.2 0.2 0.6 0.2 0.2 
T10           
  A-C1 1 1 0.71 0.05 0.06 
  A-C2 1 0.9 0.95 0.05 0.05 
T12           
  A-C1 0.33 0.33 0.5 1 0.33 
  A-C2 N/A N/A N/A N/A N/A 
T13           
  A-C1 0.13 0.13 1 0.13 0.88 
  A-C2 0.1 0.1 1 0.1 0.9 
T15           
  A-C1 0.5 0.75 1 0.5 0.5 
  A-C2 0.75 0.25 0.9 0.25 0.25 
T17           
  A-C1 0.08 0.08 0.08 0.08 0.08 
  A-C2 0.08 0.08 0.08 0.08  0.08 
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Treatment to follow-up. Single case randomization test results comparing the 
treatment phase to both follow-up periods are summarized in Table 4. Eight patients 
reported decreased fear levels at one (T5, T12) or both (T1, T6, T9, T13, T15, T17) 
follow-up periods. For avoidance, seven patients reported decreased avoidance at one 
(T5, T15) or both (T1, T3, T7, T13, T17) follow-ups. For acceptance, three patients 
reported increases (T5, T6, T17). Pain catastrophizing scores decreased for eight patients 
at one (T12) or both (T1, T6, T7, T9, T10, T13, T17) follow-ups. Pain improvement was 
reported among eight patients (T1, T3, T5, T6, T9, T10, T12, T15). 
 
Table 4. Treatment to Follow-up Randomization Test. Randomization test results determining 
significant differences between treatment and both follow-up periods (B=treatment, C1= 3 month, 
C2= 6 month). 
Patient Fear Avoidance Acceptance Catastrophizing Pain Score 
T1           
  B-C1 0.01, 0.04 0.01, 0.04 0.31, 1.0 0.01, 0.04 0.01, 0.04 
  B-C2 0.01, 0.04 0.01, 0.04 1.0, 1.0 0.01, 0.04 0.01, 0.04 
T2           
  B-C1 0.93 0.33 0.3 1 0.6 
  B-C2 0.93 0.33 0.3 1 0.6 
T3           
  B-C1 1 0.02 1 1 0.02 
  B-C2 1 0.02 1 1 0.13 
T5           
  B-C1 0.11 0.02 1 0.36 0.02 
  B-C2 0.01 1 0.02 1 1 
T6           
  B-C1 0.01 1 0.01 0.01 0.01 
  B-C2 0.01 1 0.72 0.01 0.01 
T7           
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  B-C1 1 0.03 1 0.03 1 
  B-C2 0.03 0.03 1 0.03 0.55 
T9           
  B-C1 0.01 1 0.18 0.01 0.01 
  B-C2 0.01 1                       1 0.01 0.93 
T10           
  B-C1 1 1 1 0.01 0.01 
  B-C2 1 1 1 0.01 0.01 
T12           
  B-C1 0.01 0.79 1 0.01 0.01 
  B-C2 N/A N/A N/A N/A N/A 
T13           
  B-C1 0.02 0.02 1 0.01 1 
  B-C2 0.02 0.02 1 0.02 1 
T15           
  B-C1 0.03 0.07 1 0.98 0.03 
  B-C2 0.03 0.03 0.97 0.32 0.03 
T17           
  B-C1 0.03 0.03 0.03 0.03 0.1 
  B-C2 0.03 0.03 0.03 0.03 0.39 
 
 
 
Lag analysis 
Table 5 summarizes results from the lag analyses examining at what point in 
treatment patients began to show a significant improvement in their diary measures. 
Fear. Six patients (T1, T5, T7, T9, T12, and T13) showed a lag effect for fear 
during the course of treatment with the lag ranging from 23 days to 191. T17 did not 
show a lag effect for fear. A lag analysis was not performed for patients T6 and T15 in 
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regards to fear as they already showed a significant difference when comparing just 
baseline and treatment values. 
Acceptance. Four patients (T1, T2, T5, and T6) showed a lag effect for acceptance 
during the course of treatment, ranging from 4 to 104 days. Patients T7 and T12 also 
showed a lag effect during the course of treatment, but in the opposite direction from 
what was expected. A lag effect for T17 was seen at the three-month follow-up. No lag 
effect was seen for the other five patients. 
Avoidance. A lag effect for avoidance was seen in seven patients (T1, T2, T3, T5, 
T9, T10, and T13) during the course of treatment. Lag effect ranged from 9 to 191 days. 
Patients T7, T15, and T17 didn’t show a lag effect for avoidance until follow-up. Note for 
patient T6 a lag analysis was not completed as patient showed a significant difference for 
avoidance when just comparing baseline to treatment values.  
Catastrophizing. Patients T1 and T9 exhibited a lag effect for catastrophizing 
during the course of treatment, ranging from 45 to 195 days. A lag analysis was not 
performed for T2, T3, T6, and T15 as they showed a significant difference between just 
baseline and treatment values.  Five patients (T5, T10, T12, T13, and T17) showed lag 
effect at follow-up. Patient T7 did show a lag effect during the course of treatment, but 
with increasing catastrophizing scores. 
Pain. A lag effect for was exhibited by seven patients (T1, T5, T7, T9, T10, T12, 
and T13) over the course of treatment, ranging from 6 to 191 days. The analysis was not 
performed for patient T6 as this patient had a significant difference between baseline and 
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treatment to begin with. Patient T3 showed a lag effect during the course of treatment, 
but with increasing pain scores. Patient T17 did not show a lag effect until follow-up.    
 
Table 5. Lag Effect. The effect lag showing the point at which a significant p-value was reached after 
repeating the randomization tests with one lag equally 1 day. (# indicates lag effect was not seen until 
follow-up period). *indicates lag was not until follow-up period, ^ indicates change was in direction 
opposite from expected 
Patient Fear Acceptance Avoidance Catastrophizing Pain Score 
T1 124 (p=0.06), 
191 (p=0.06) 
n/a, 190 
(p=0.05) 
124(p=0.06), 
191(p=0.05) 
122(0=0.06), 
195 (p=0.06) 
40 (p=0.03), 
191 (p=0.05) 
T2 no lag 14 (p=0.05) 9 (p=0.03) n/a n/a 
T3 
no lag no lag 67 (p=0.06) n/a ^52(p=0.052) 
T5 53 (p=.06) 4 (p=.03) 27 (p=0.06) 65 (p=0.03)* 11 (p=.06) 
T6 n/a 104 (p=0.06) n/a n/a n/a 
T7 23 (p=0.02) ^35 (p=0.05) 52 (p=0.05)* ^2 (p=0.049) 40 (0=0.05) 
T9 74 (p=0.05) no lag 64 (p=0.04) 74 (p=.06) 74 (p=0.05) 
T10 no lag no lag no lag 76 (p=0.01)* 4 (p=0.06) 
T12 ^52 (p=.044) ^14 (p=.053) 51 (p=0.06) 129 (p=0.01)* 77 (p=0.06) 
T13 71 (p=0.01) no lag 61 (p=0.05) 71 (p=0.06)* 6 (p=0.04) 
T15 n/a no lag 70 (p=0.02)* n/a n/a 
T17 45 (p=0.02)* 45 (p=0.06)* 45 (p=0.02)* 45  (p=0.05)* 45 (p=0.06)* 
 
 
Effect size 
Effect size was calculated using the non-overlap of all pairs (NAP), cutoffs for 
interpreting NAP values were taken from Parker et al 2011. They report that for a 
measure in which the score is increasing (e.g. acceptance) a NAP value of 0.85-1.0 
indicates a large effect, 0.32-0.84 a medium effect, and 0-0.31 weak to no effect. For a 
 34 
measure in which the score is expected to decrease (e.g. fear, avoidance, catastrophizing, 
and pain) a large effect is indicated by a NAP value between 0.93-1.0 and a medium 
effect 0.66-0.92.  A value less than 0.66 indicates a weak/no effect. Table 6 and 7 reports 
the effect sizes (NAP) when comparing baseline to treatment and follow-up data for all 
five domains of the daily diaries. Also, reported in the table are the test statistics, which 
are the mean differences between the phases. Table summarizes the effect sizes 
comparing treatment to follow-up. 
Baseline to treatment. The largest number of patients reported clinically 
significant (medium or large effect size) changes in acceptance (T1, T2, T3, T5, T7, T9, 
T10, T13, T15, T17), with four patients reporting clinically significant improvements in 
fear (T2, T5, T6, T9), avoidance (T1, T2, T6, T9), and pain (T1, T2, T9, T12) and three 
reported improvements in pain catastrophizing (medium effects; T1, T6, T15).  
 
Table 6. Baseline to Treatment Effect Size. Test statistics (difference in phase means) and effect 
sizes (NAP) for each daily diary domain comparing baseline to treatment (A-B). NAP is percentage of 
non-overlap of all pairs. 
Patient Fear Avoidance Acceptance Catastrophizing Pain Score 
T1 
-3.71(0.18), 
0.29(0.63) 
-2.94(0.08),  2.56 (0.10), -
0.38 (0.54) 
-1.57 (0.24), 0.38 
(0.69) 
0.42 (0.60), 
1.62 (0.91) 1.21 (0.83) 
T2 0.92 (0.72) 1.46 (0.74) -1.25 (0.80) 0.29 (0.56) 3.47 (0.96) 
T3 0.36 (0.59) -0.26 (0.35) -0.18 (0.55) 0.27 (0.64) -0.77 (0.26) 
T5 0.88 (0.70) 0.10 (0.52) -0.91 (0.91) 0.01 (0.53) -0.19 (0.46) 
T6 0.77 (0.72) 4.98 (0.98) -0.91 (0.91) 0.80 (0.90) 0.33 (0.62) 
T7 -0.23 (0.40) 0.17 (0.54) 0.23 (0.45) -0.89 (0.31) -0.29 (0.41) 
T9 1.21 (0.71) 2.63 (0.89) -0.49 (0.60) 0.18 (0.54) 1.04 (0.68) 
T10 0 (0.50) 0.09 (0.54) 0.38 (0.36) -0.04 (0.48) -0.05 (0.47) 
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T12 -2.39 (0.03) 0.92 (0.65) 2.08 (0.15) -2.58 (0.03) 1.07 (0.68) 
T13 0.04 (0.47) 0.11(0.43) 0.53 (0.41) -1.79 (0.1) 0.73 (0.61) 
T15 0.39 (0.51) -1.64 (0.004) -0.18 (0.58) 0.75 (0.81) -0.64 (0.22) 
T17 1.18 (0.58) -0.66 (0.37) -2.49 (0.79) -0.93 (0.35) 1.18 (0.58) 
 
Baseline to Three-month follow-up. Eleven patients reported clinically 
significant changes for acceptance when comparing baseline to three-month follow-
up, with seven (T1, T3, T6, T9, T12, T13, and T17) patients reporting large effects 
and four (T2, T5, T7, and T10) medium effects. Seven patients had significant effect 
sizes for fear (large; T1, T5, T9, T12, T13, T17 and medium; T2). For the avoidance 
domain eight patients reported clinically significant improvement (large effect size; 
T1, T5, T6, T13, and T15 and medium effect size; T2, T7, T12, and T17).  Significant 
effect sizes (medium or large) for catastrophizing were seen in five patients (T1, T6, 
T9, T10, and T17). Eight patients (T1, T2, T5, T9, T10, T12, T15, and T17) reported 
significant effect size for pain. Results are summarized in Table 7. 
Baseline to Six-month follow-up. Similar to three-month follow-up eleven 
patients (T1, T2, T3, T5, T6, T7, T9, T10, T13, T15, and T17) reported clinically 
significant effect sizes (large or medium) for acceptance. Eight patients (T1, T2, T5, 
T6, T7, T9, T13, and T17) had medium or large effect sizes for fear. Also, for eight 
patients (T1, T2, T3, T6, T7, T9, T13, and T17) clinically significant effect sizes were 
reported for avoidance. Catastrophizing scores showed seven patients (T1, T6, T7, 
T9, T10, T15, and T17) had either medium or large effect sizes. Eight patients (T1, 
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T2, T6, T9, T10, T15, and T17) had medium or large effect sizes for pain. Results are 
summarized in Table 7. 
 
Table 7.  Baseline to Follow-up Effect Size. Test statistics (difference in phase means) and effect 
sizes (NAP) for each daily diary domain comparing baseline to 3-month and 6-month follow-up (A-
C1, A-C2). NAP is percentage of non-overlap of all pairs.  
Patient Fear Avoidance Acceptance Catastrophizing Pain Score 
T1 STAT (NAP) STAT (NAP) STAT (NAP) STAT (NAP) STAT (NAP) 
  A-C1 
6 (0.97), 3.29 
(1.0) 
8.92 (1.0), 
8.95 (1.0)  
-3.65 (1.0), -
3.20 (1.0) 
5.29 (1.0), 3.38 
(1.0) 
6.47 (1.0), 
4.63 (1.0) 
  A-C2 
6 (0.97), 3.92 
(1.0) 
4.29 (1.0), 
3.21 (1.0) 
-9.35 (1.0), -
9.375 (1.0) 
5.29 (1.0), 3.375 
(1.0) 
6.47 (1.0), 
4.625 (1.0) 
T2           
  A-C1 1.12 (0.76) 1.59 (0.82) -2.14 (0.88) 0.29 (0.56) 4.51 (1.0) 
  A-C2 
1.117647 
(0.76) 
2.352941 
(0.88) 
-1.588235 
(0.82) 
-0.2773109 (0.48) 
4.512605 
(1.0) 
T3           
  A-C1 1.88 (.59) 0.18 (0.55) -1.64 (1.0) 0.27 (0.64) -0.61 (0.3) 
  A-C2 
0.3636364 
(0.59) 
1.636364 
(1.0) 
-0.1818182 
(0.54) 
0.2727273 (0.64) 
-1.467532 
(0.0) 
T5           
  A-C1 4.39 (1.0) 2.75 (0.98) -1.29 (0.84) 0.16 (0.54) 0.43 (0.66) 
  A-C2 
0.8181818 
(0.72) 
0.2857143 
(0.63) 
0.2467532 
(0.41) 
-1.987013 (0.16) 
-2.142857 
(.04) 
T6           
  A-C1 1.24 (0.14) 1.53 (1.0) -5.7 (1.0) 2.23 (0.71) 0.97 (0.57) 
  A-C2 
1.528571 
(0.88) 
5.7 (1.0) 
-1.528571 
(1.0) 
2.942857 (1.0) 
0.9714286 
(0.86) 
T7           
  A-C1 -0.08 (0.47) 0.77 (0.86) -1.6 (0.8) -0.68 (0.26) -1.08 (0.12) 
  A-C2 
0.9166667 
(0.86) 
4.02381 (1.0) 
-0.9166667 
(0.88) 
0.6071429 (0.85) 
-0.4047619 
(0.38) 
T9           
  A-C1 5.43 (1.0) 
5.428571 
(1.0) 
-0.43 (0.57) 
 
4.29 (1.0) 1.57 (0.81) 
  A-C2 
5.142857 
(1.0) 
5.428571 
(1.0) 
-0.5714286 
(0.63) 
3.714286 (1.0) 
1.428571 
(0.75) 
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T10           
  A-C1 0 (0.5) 0 (0.35) 0 (0.54) 0.95 (0.98) 1.44 (0.75) 
  A-C2 0 (0.5) 
0.08695652 
(0.54) 
-3.136646 
(1.0) 
1.956522 (1.0) 
1.583851 
(0.87) 
T12           
  A-C1 5.29 (1.0) 2.54 (0.9) 0.63 (0.3) -0.26 (0.46) 7.71 (1.0) 
  A-C2 N/A N/A N/A N/A N/A 
T13           
  A-C1 2.71 (1.0) 3.71 (1.0) -4.5 (1.0) -0.29 (0.43) 0.71 (0.63) 
  A-C2 2.2 (1.0) 3.71 (1.0) 
-3.971429 
(1.0) 
-0.6(0.32) 
0.08571429 
(0.73) 
T15           
  A-C1 0.17 (0.42) 1.43 (0.95) -1.52 (.02) 0.21 (0.61) 0.4 (0.71) 
  A-C2 
0.3095238 
(0.5) 
0.04761905 
(0.52) 
-1.857143 
(0.99) 
0.5 (0.75) 
1.119048 
(0.94) 
T17           
  A-C1 5.95 (0.99) 3.59 (0.86) -5.74 (0.92) 3.9 (0.92) 6.83 (1.0) 
  A-C2 9.38 (1.0) 6.60 (1.0) 0.27 (0.5) 5.75 (0.99) 6.43 (0.96) 
 
Treatment to Three-month follow-up. Eleven patients (T1, T2, T3, T5, T6, T7, 
T9, T12, T13, T15, and T17) had either medium or large effect sizes for acceptance, 
eight patients (T1, T2, T5, T7, T9, T12, T13, and T17) for fear, eight patients (T1, T3, 
T5, T7, T9, T12, T13, and T17) for avoidance, and seven patients (T1, T6, T9, T10, 
T12, T13, and T17) for catastrophizing. For eight patients (T1, T2, T5, T6, T10, T12, 
T15, and T17) medium or large effect sizes were seen for pain. Results are 
summarized in Table 8. 
Treatment to Six-month follow-up. Nine patients (T1, T2, T3, T6, T7, T9, T10, 
T13, and T15) reported either medium or large effect sizes for acceptance. For seven 
patients (T1, T2, T6, T7, T9, T13, and T17) medium or large effect sizes were reported in 
the fear domain.  Seven patients (T1, T6, T7, T9, T10, T13, and T17) had either medium 
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or large effect sizes for catastrophizing. Six patients (T1, T2, T6, T10, T15, and T17) had 
either medium or large effect sizes for pain. Seven patients (T1, T3, T5, T7, T9, T13, and 
T17) reported medium or large effect sizes for avoidance.  
 
Table 8.  Treatment to Follow-up Effect Size. Test statistics (difference in phase means) and effect 
sizes (NAP) for each daily diary domain comparing treatment to 3-month and 6-month follow-up (B-
C1, B-C2). NAP is percentage of non-overlap of all pairs. 
Patient Fear Avoidance Acceptance Catastrophizing 
Pain Score 
 
T1 STAT (NAP) STAT (NAP) STAT (NAP) STAT (NAP) STAT (NAP) 
  B-C1 
9.71(1.00), 
3.00 (1.00) 
7.23 (1.00), 
2.0 (1.00) 
0.09 (0.49), -
8.57 (1.00)  
6.86 (1.00), 3.0 
(1.00) 
6.86 (1.00), 
3.0 (1.00) 
  B-C2 
9.71 (1.00), 
3.00 (1.00) 
7.23 (1.00), 
2.00 (1.00 
-11.91 
(1.00), -9.00 
(1.00) 
6.86 (1.00), -3.00 
(1.00) 
6.05(1.00), 
3.00 (1.00) 
T2           
  B-C1 0.19 (0.67) 0.89 (0.61) -0.33 (0.51) 0 (0.50) 1.04 (0.83) 
  B-C2 0.19 (0.67) 0.89 (.61) -0.33 (0.51) -0.57 (0.43) 1.04 (0.83) 
T3           
  B-C1 0 (0.50) 1.9 (1.00) 0 (0.50) 0 (0.50) 0.15 (0.54) 
  B-C2 0 (0.5) 1.90 (1.00) 0.00 (0.5) 0 (0.5) -0.7 (0.26) 
T5           
  B-C1 3.51 (0.97) 1.19 (0.83) -1.84 (0.91) 0.22 (0.58) 0.62 (0.69) 
  B-C2 -0.06 (0.51) 3.90 (1.00) 1.16 (0.22) -1.78 (0.06) -1.95 (0.08) 
T6           
  B-C1 0.48 (0.64) 0.72 (0.59) -0.19 (0.59) 1.43 (0.86) 0.65 (0.78) 
  B-C2 0.76 (0.80) 0.72 (0.59) -0.62 (0.76) 2.14 (1.00) 0.65 (0.84) 
T7           
  B-C1 4.00 (1.00) 1.43 (0.79) 1.00 (0.94) 0.21 (0.52) 0.83 (0.17) 
  B-C2 1.14 (0.93) 3.86 (1.00) -1.14 (1.00) 1.5 (0.95) -0.12 (0.47) 
T9           
  B-C1 4.22(0.99) 2.80 (0.90) 0.06 (0.47) 4.11 (1.0) 0.53 (0.61) 
  B-C2 3.93 (0.99) 2.80 (0.90) -0.08 (0.54) 3.54 (0.99) 0.39 (0.57) 
T10           
  B-C1 0 (0.50) 0 (50) 0.05 (0.49) 1.00 (1.00) 1.49 (0.78) 
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  B-C2 0 (0.5) 0 (0.5) -3.52 (1.00) 2.00 (1.0) 1.63  (0.91) 
T12           
  B-C1 7.28 (1.00) 1.97 (0.76) -0.99 (.75) 2.32 (0.95) 6.65 (1.00) 
  B-C2 N/A N/A N/A N/A N/A 
T13           
  B-C1 2.67(0.99) 4.39 (1.00) -4.24 (1.00) 1.5 (0.91) 0.01 (0.52) 
  B-C2 2.16 (0.99) 3.59 (0.99) -4.5 (1.00) 1.19(0.86) -0.64 (0.49) 
T15           
  B-C1 -0.23 (38.64) 0.12(0.56) -1.25 (0.95) -10.54 (0.27) 1.05 (0.83) 
  B-C2 -0.08 (0.47) 1.69 (0.56) -1.68 (0.99)  0.25 (0.38) 1.76 (0.98) 
T17           
  B-C1 5.99 (0.99) 6.40 (1.00) -1.10 (0.66) 4.83 (0.95) 5.65 (0.91) 
  B-C2 9.42(1.00) 7.26 (1.00) 2.76 (0.25) 6.69 (0.99) 2.79 (0.74) 
      
 
Summary of Results 
 Presented in Table 9 is a general overview comparing the results from all the 
statistical analyses that were completed in this investigation: visual analysis, SCRT, 
lag analysis, and effect size. 
Table 9. Summary of Results. Overview of results for fear and avoidance across all statistical 
analyses. A significant result is indicated by a check mark, no response is indicated by an x-mark,  
and N/A is represented by a hyphen. Note that the follow-up row represents a significant result  
when comparing baseline to follow-up or treatment to follow-up.  
Patient Phase Visual 
Analysis 
SCRT Lag 
Effect 
Effect 
Size 
T1 Treatment ✓ ✓ ✗ ✗ ✓ ✓ ✗ ✓  
 Follow-up ✓ ✓ ✓ ✓ -   -  ✓ ✓  
T2 Treatment ✓ ✓ ✗ ✗ ✗ ✓  ✓ ✓  
 Follow-up ✓ ✓ ✗ ✓ ✗ -    ✓ ✓  
T3 Treatment ✗ ✗  ✗ ✗ ✗ ✓ ✗ ✗  
 Follow-up ✗ ✓ ✗ ✗ ✗ -   ✗ ✓  
T5 Treatment ✓ ✗ ✗ ✗ ✓ ✓ ✓ ✗  
 Follow-up ✓ ✓ ✓ ✓ -   -   ✓ ✓  
T6 Treatment ✗ ✓ ✓ ✓ -   -   ✓ ✓  
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 Follow-up ✓ ✓ ✓ ✗ -  -   ✓ ✓  
T7 Treatment ✗ ✗ ✗ ✗ ✓ ✗ ✗ ✗  
 Follow-up ✓ ✓ ✓ ✓ -   ✓  ✓ ✓  
T9 Treatment ✓ ✓ ✗ ✗ ✓ ✓ ✓ ✓  
 Follow-up ✓ ✓ ✓ ✗ -   -   ✓ ✓  
T10 Treatment ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗  
 Follow-up ✗ ✗ ✗ ✗ ✗ ✗   ✗ ✗  
T12 Treatment ✗ ✓ ✗ ✗ ✓ ✓ ✗ ✗  
 Follow-up ✓ ✓ ✓ ✗ -   -   ✓ ✓  
T13 Treatment ✗ ✓ ✗ ✗ ✓ ✓ ✗ ✗  
 Follow-up ✓ ✓ ✓ ✓ -   -   ✓ ✓  
T15 Treatment ✗ ✗ ✓ ✗ -   ✗  ✗ ✗  
 Follow-up ✗ ✗ ✓ ✓ -  ✓  ✗ ✓  
T17 Treatment ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗  
 Follow-up ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  
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DISCUSSION 
 
Interpretation of results 
The primary of aim of this investigation is to demonstrate the applicability of a 
single-case analysis in assessing improvement in chronic pain patients undergoing a 
cognitive behavioral therapy intervention. Single case analysis allows for a more patient 
centric treatment, and for conclusions to be made in regards to individual patient 
responses. Several different methodologies were employed to assess improvement in the 
patients, with the most rudimentary being visual analysis. Visual analysis allows you to 
track changes in an individual patient throughout time. Importantly it allows you to 
determine if a given change in a measure is part of a greater trend or a fluctuation in the 
reporting. For example, if we consider the avoidance scores for patient T9 we see there is 
a clear downward trend throughout treatment, which is maintained at follow-up. 
However, now consider the avoidance scores for Patient T2, where we see a decrease in 
avoidance between baseline and follow-up. If we look at the trend for this patient we see 
significant variability throughout treatment, which cast doubt as to whether or not the 
changes reflect a real change or are a part of the fluctuation pattern. Visual analysis also 
provides solid evidence that T1, T6, T12, and T13 had improvement in avoidance. When 
there are clear trends, as is the case with the patients listed above, it seems plausible to 
use visual analysis as a way to assess improvement. Several other patients showed these 
trends across several different domains. Patients T1 and T9 in particular showed 
improvement across almost all domains based on visual analysis. The other 
methodologies used to assess improvement can help add additional rigor to conclusions 
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based on visual analysis, and perhaps assess the data in a more nuanced manner. 
Potentially there could be significant differences between two phases, but without a 
definite trend it might be difficult to make conclusions solely on visual analysis.  Pain 
scores for patient T6 based on visual analysis do show a downward trend, however, the 
trend is not nearly as compelling as the decrease the patient has for avoidance.  
The single case randomization test can be used to determine significance between 
two phases. This type of analysis is uniquely suited for an N-of-1 approach as it takes 
into account the correlation between adjacent time points. When this analysis was 
performed for T6 pain data a significant difference was found between baseline and 
treatment, indicating that a change in pain was seen for this patient. Similar significant 
differences were found for T6 in the fear, avoidance, and catastrophizing domains. 
Interestingly, very few patients showed a significant difference between the baseline and 
treatment phases. Consider patients T1 and T9, despite showing clear trends of 
improvement across most domains, the randomization tests do not indicate improvement. 
An explanation for this incongruence is there is delay in when improvement actually 
occurs for these patients. So that when you compare baseline to treatment, there is a 
significant amount of treatment time points that do not vary from the baseline time 
points. In these circumstances additional techniques are needed to add rigor to the single 
case randomization test. The lag analysis is well suited to account for this delay in 
treatment response. It allows us to determine at what point in a phase a significant change 
happens. When this is done for patients T1 and T9 we see that there is a lag effect across 
all domains and can conclude a statistically significant change occurred. Congruency 
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between the lag analysis and visual analysis can be seen when we consider avoidance 
scores for patients T1, T2, T9, T13, and T12. Visual analysis showed improvement 
during treatment, but the randomization test comparing baseline to treatment in these 
patients did not demonstrate significance. In all of these patients significance was found 
using the lag technique. This highlights how visual analysis and lag analysis can be 
synergistically combined to demonstrate improvement in patients.  
There can be circumstances in which, despite trends of improvement being 
demonstrated during treatment, a lag effect is still not seen during the treatment period. 
T17 pain scores are an example of this. We see that during treatment the patient's pain 
score does improve based solely on visual analysis, however, when doing the lag analysis 
we are unable to capture this significance. In this case when we include the follow-up 
data, where there continues to be a decrease in the pain score, a significant change in pain 
is seen. In this particular case, along with several others where we do not see a lag effect 
until follow-up, it appears that even if improvement does begin during treatment we may 
not have enough treatment time points to claim significance. This finding gives a reason 
for using visual analysis in combination with lag analysis during treatment, as it could 
provide insight into whether treatment should be extended.  
 The single-case randomization test was also used to determine significance 
between the baseline and follow-up periods and the treatment and follow-up periods. 
Very few patients, based on the SCRT results, showed significance between the baseline 
and follow-up periods. This represents another incongruence in the data analysis. Notice 
patient T9 shows a great difference between baseline and treatment values across several 
 44 
domains, but based on the SCRT there is no significant difference between the baseline 
and treatment values. A similar pattern is seen in the analysis of the avoidance scores in 
patient T6. As previously discussed in regards to the lag analysis, it could be that there 
are not enough time points, showing improvement, to establish significance. This does 
seem likely as the follow-up period is only seven days. Furthermore, the absence of 
statistical significance could be further compounded by not having a long enough 
baseline period. Interestingly, when comparing treatment to follow-up scores, many more 
patients were seen to display significant differences between these two time periods. The 
discrepancy of significance between these two comparisons strengthens the claim that 
there are just not enough time points being compared in the baseline to follow-up 
analysis. A good example of this particular incongruence is when we consider the 
avoidance and fear scores for patient T17.  Considering the time series graphs you will 
observe that this patient shows considerable improvement in these domains at the three 
and six month follow-up. However, the randomization test comparing these two time 
points does not indicate any significance, but the randomization test comparing treatment 
to follow-up does demonstrate significance. Visual analysis shows there is little 
difference between the baseline and treatment periods for both domains, strengthening 
the claim there are not enough time points in the baseline and follow-up periods to 
compare. A similar argument can be made for T3 avoidance, T6 catastrophizing, T7 fear, 
T15 pain, and T12 fear and pain. Fortunately, the higher frequency of statistical 
differences between the treatment and follow-up periods does indicate that change is 
occurring in these patients. Especially when we consider these significant changes in 
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combination with visual analysis.  Visual analysis helps give an idea of what 
changes/trends are occurring in the patient and the other analyses help provide statistical 
rigor to claim significance.  
 Another way to analyze the single case data apart from randomization tests is to 
calculate the effect size. This allows us to compare phases in a somewhat more nuanced 
manner and allows claims to be made regarding the magnitude of change a patient 
experiences.  In this study the non-overlap of all pairs (NAP) was used to calculate effect 
size. Very few medium and large effect sizes were seen when comparing the baseline and 
treatment periods. This is congruent with the finding of few significant differences found 
between those two phases using the randomization test. Recall the lag effect was needed 
to show significant changes happening during the course of treatment.  The effect size 
methodology utilizes how much overlap there is in values between two phases to then 
quantify how large of a change has occurred. When we consider many patients had a 
delayed response to treatment, in makes sense that an effect size calculation would 
demonstrate considerable overlap in the phases being compared. Nonetheless some 
patients did demonstrate change based on effect size, for example nine patients had a 
medium effect size for acceptance. Comparison of baseline to follow-up and treatment to 
follow-up is when effect size seemed to shed the most insight. Randomization tests 
comparing baseline to follow-up demonstrated significant differences in avoidance scores 
for three patients, whereas calculation of effect size comparing the same time points 
showed nine patients had large effect sizes. In this way the effect size does not appear to 
be limited when only a small number of time points are being compared. Patient T13’s 
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avoidance data demonstrates this nicely. From the time series graph we see avoidance 
begins to decrease towards the end of treatment and then decreases further at the three 
and six month follow-up time point. Effect size comparing baseline to treatment does not 
indicate a change (as expected due to the delay in treatment response). Randomization 
tests comparing baseline to follow-up do not indicate a significant difference, despite a 
3.7 point difference between the averages of these two phases, but the effect size for this 
comparison indicates a large change. The avoidance scores for T13 also demonstrate 
thorough congruency between the effect size analysis and the visual and lag analysis 
(both of which show improvement).  Other examples of this same pattern include T13 
fear, T17 fear, avoidance, catastrophizing, and pain, T6 avoidance and acceptance, T9 
fear, avoidance, acceptance, and catastrophizing, and T12 pain, and T10 acceptance 
scores.  
 It is important anytime you are using multiple techniques to analyze data to look 
closely for congruency or lack of congruency between the different methodologies. For 
this particular study both were seen. Patients T1 and T9 are good examples of 
congruency as they both showed improvement across most domains for all the different 
analytic methodologies. As mentioned previously there were many other examples of 
congruency between the various analyses. Unfortunately, there were several examples of 
incongruency that are worth mentioning. In particular, examples where the single case 
randomization test indicated significance between baseline and treatment values, but all 
other analyses, such as visual, lag, and effect size, did not demonstrate any improvement 
when comparing these phases. Fear scores for T15 and catastrophizing scores for T3 and 
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T2 highlight this inconsistency. Further investigation reveals that an unstable baseline 
period was present in all of these examples. A reasonable conclusion is that due to this 
variability a few outlying values in the baseline phase are skewing the results, thus it 
appears there is a significant improvement when based on the other analyses this is not 
the case.  Reliance on one statistical methodology in assessing improvement during a 
single case study is seriously questioned by these findings.    
 One additional incongruency is in regards to the lag analysis. For some cases, 
such as T7 and T10 pain scores and T5 avoidance scores, the lag analysis revealed a 
significant change occurred during the treatment, however, when we observe the time 
series graphs no improvement trend is seen during the treatment phase. Variability could 
be the culprit again here, with a few outlying time points causing certain groupings of the 
data to appear significantly different. Unfortunately, the way we constructed the time 
series graphs does not allow us to see this variability that might be occurring on day-to-
day basis.    
 A secondary aim was to assess the overall efficacy of the GET Living 
intervention in chronic pain patients using the daily diary measure. Some patients (T1, 
T9, T12) showed improvements in several domains, suggesting that in these patients the 
intervention was particularly effective in targeting issues related to their chronic pain. All 
patients showed improvement in at least one domain. Considering trends in improvement 
across all patients we see that the intervention was particularly effective in targeting a 
patient’s avoidance of painful activities. Visual analysis shows that nine of the twelve 
patients showed a decrease in their avoidance scores, effect size comparing baseline 
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scores to follow-up scores reveals a similar ratio. This is a very encouraging sign as a 
primary goal of GET Living is to help individuals be more engaged in valued activities. 
 
Results in the context of the literature 
 In their day-to-day work a clinician’s chief concern should be how they can help 
their individual patients. Randomized control trials play an important role in advancing 
our understanding of certain pathologies and how to best treat disease. However, RCTs 
are limited in their ability to provide clinicians with specific information about an 
individual patient’s response. When we consider a pathology such as chronic pain, for 
which a tailored treatment plan might be needed, an additional method is needed to assess 
a patient’s response to an intervention. This dilemma that clinicians face was highlighted 
by Davidson et al 2014 as a way to advocate for more utilization of the single case 
methodology in assessing psychological interventions. The results of our study give 
further evidence as to how a single case design and data analysis can give great insight 
into how an individual patient responds to treatment. Note that each patient had fairly 
unique responses to the GET Living intervention when we consider all of the domain 
measures. The methodology we presented could be employed by clinicians when 
deciding on what type of intervention would be most efficacious for a particular chronic 
pain patient, along with what outcomes are most sensitive to treatment response. 
Importantly we demonstrated that a single case design can be analyzed in a statistically 
rigorous manner. One of the big strengths of RCTs is they possess a great deal of rigor, 
but we demonstrated that a single case design need not lack this rigor. Duan et al 2013 
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explain that when systematic measures are not used, reliability, validity, and replicability 
of results can be disputed. Despite some incongruencies, we did demonstrate a systematic 
way to measure treatment response using a single case design.  
 To assess the efficacy of CBT in a group of patients with hoarding disorder 
Pollock et al 2013 demonstrated the potential of using a single case design to assess the 
efficacy of their intervention. Interestingly, they showed how the methodology could be 
used over a long period of time, tracking an individual patient’s treatment response 
throughout the entire intervention. We demonstrated how a similar methodology could be 
used to assess a CBT intervention in chronic pain patients. Similar to Pollock et al 2013 
we were able to employ a methodology to track an individual patient’s improvement 
throughout the intervention rigorously. Especially, when we consider visual and lag 
analysis being performed in tandem. The visual analysis gives us a relative trend in a 
patient’s response to the intervention, and the lag analysis adds the necessary statistical 
rigor in making conclusions about a patient’s improvement. Other investigators who have 
employed a single case design to assess CBT included de Jong et al 2012, who assessed a 
pain intervention in an adult population. In our study we show the applicability of a 
similar methodology in a pediatric pain group. 
 One unique aspect of our intervention was its longitudinal nature (treatment was 
delivered over a significant amount of time). A big advantage of a single case experiment 
is that it involves taking repeated measurements over a long period of time (Onghena et 
al 2005). In this investigation we showed how the single case methodology is uniquely 
aligned to the very way in which our treatment was delivered. Another advantage of a 
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single case experiment discussed by Onghena et al 2005 is that it is ideal for 
individualized measurement scales. Each patient’s pain experience is so specific to that 
individual that comparing changes across patients could prove to be difficult. Our single 
case design allows us to determine change for an individual patient even if the 
improvement is quantitatively much different than another patient’s response. Consider 
the pain score for patient T6, although there was not a large numeric decrease, we did 
show a statistically significant change occurred. 
 A few other limitations of randomized control trials include the need for a large 
sample size and the homogeneity of study participants (Lillie et al 2011). In our study we 
were able to show that despite a small sample size we can still make statistical claims 
about a patient’s response to treatment. Furthermore, we were able to test our 
intervention across a heterogeneous patient group. If our treatment was to be assessed 
using a randomized control trial many of our patients would probably have been excluded 
from the study due to comorbidities or other exclusionary criteria. However, when we 
consider the daily work of a clinician, he/she is interested in figuring out how to help 
his/her individual patients, who will possess comorbidities and other unique 
characteristics.    
 In addition to demonstrating the applicability of a single case methodology, we 
also provided a way in which you can quantify patient improvement. Parker and Vannest 
2009 discuss how calculating the non-overlap of all pairs can be used to make more 
precise conclusions about the degree of improvement. We were able to apply this 
methodology to assess improvement across our domains of interest. This could 
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potentially be very useful to a clinician who might be interested in comparing multiple 
interventions, and then selecting which would be most beneficial for a particular patient. 
It also adds an additional way to consider differences between two phases, particularly 
when a methodology such as single case randomization is not detecting a significant 
change (even when visual analysis is showing a considerable improvement).    
 
Limitations 
As mentioned already there were some incongruencies in our data analysis, which 
point to some of the limitations of a single case design. One of the biggest issues that can 
plague a single case analysis is a lack of a stable baseline period, as was observed for 
patients T15 fear and T5 acceptance scores. If patients do not respond consistently during 
this period it becomes difficult to make conclusions about a patient’s response to 
treatment. Similarly if there is a great deal of variability during the treatment phase (i.e. 
no noticeable trend) it can be equally difficult to make conclusions. Another limitation, 
which relates to the idea of variability, has to do with the actual assessment tool (the daily 
diary) patients complete. Given that the score for each domain is based on multiple items 
from the daily diary, if patient’s answers do not show consensus between the items for an 
individual domain it could call into question whether the items are sensitive to change.   
  
Future Directions 
In reference to limitations listed above the next crucial step will be determining if 
there is variability between items in a given domain. This will help ensure that our daily 
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diaries are sensitive to change and are an adequate representation of the domains of 
interest. Variability in scores, without a noticeable trend, appear to be responsible for 
some of the inconsistencies between our different analytical methodologies. Future 
experimentation, which extends baseline and treatment phases to establish more stability, 
will definitely be helpful in determining whether this is the culprit. Also, it would be 
interesting to use visual analysis in tandem with lag analysis during the treatment phase 
to make decisions about extending this phase. For example, if a patient begins to show 
improvement based on appearance of a time series graph (the clinician) can extend 
treatment to see if lag analysis detects a significant change. Previously, it was discussed a 
single case design can be used to compare multiple interventions in a single patient, and 
then from this data make future treatment decisions. An investigation that uses a single 
case design to compare GET Living to other chronic pain interventions would further 
demonstrate the ability of this design to help clinicians make patient centric decisions.     
 
Summary 
Overall a single case data analysis methodology can be a valuable tool in 
assessing improvement in patients, and should be considered by clinicians when making 
therapy decisions. In this study, assessing improvement in a CBT pain intervention, a 
single case series can allow us to make statistically rigorous claims about individual 
patient responses. However, single case series can present with incongruencies that can 
be difficult to reconcile. The biggest hurdles that need to be overcome are ensuring stable 
baseline periods and using measures that ensure this stability. It can also be difficult to 
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rely on one method to assess a single case study as this can exacerbate incongruencies, 
combining results from several statistical tests can fight against this unwanted outcome. 
The methodology we present in this investigation provides a patient-centric data analysis 
that could provide to be useful in other investigations particularly ones involving 
cognitive behavioral therapy.  
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